Eurand Pharmaceuticals Ltd. initiated the rolling submission of its NDA with the FDA for Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI), a deficiency of digestive enzymes normally produced by the pancreas that can result from a number of diseases, including cystic fibrosis, chronic pancreatitis, and pancreatic cancer. Zentase, the company’s lead product candidate, has been granted fast-track designation by the FDA. Zentase is a pancreatic enzyme product (PEP) des...